OVID News and Press, Ovid Therapeutics Inc. From 09/24/19

OVID stock is one of the biggest penny stock gainers in the biotech sector this week after Ovid Therapeutics Inc (NASDAQ:OVID) reported preliminary results from a Phase 2 open-label extension study. Positive Momentum Ovid Therapeutics has been one of the more interesting companies in th...

Gainers:  Ovid Therapeutics (NASDAQ: OVID ) +27% . VolitionRx Limited (NYSEMKT: VNRX ) +24% . Cellcom Israel (NYSE: CEL ) +21% . Wheeler Real Estate Investment Trust (NASDAQ: WHLR ) +19% . Fresh Del Monte Produce (NYSE: FDP ) +16% . New Age Beverages Corporation (NASDAQ: NBEV ) ...

Thinly traded nano cap Ovid Therapeutics ( OVID +6.7% ) is up on below-average volume on the heels of preliminary results from a Phase 2 open-label extension study evaluating soticlestat (OV925/TAK-935) in patients with rare developmental and epileptic encephalopathies, including Drave...

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare Epilepsies; Initial Data from Phase 2 ARCADE Trial Anticipated in Q1 ...

"Miracles are like pimples, because once you start looking for them, you find more than you ever dreamed you'd see ." - Lemony Snicket, The Lump of Coal Today we take a look a developmental biotech concern that is deep in "Busted IPO" territory. However, if things fall right for the compa...

The first patient has been randomized in a Phase 3 clinical trial, NEPTUNE, evaluating Ovid Therapeutics' ( OVID -3.2% ) lead candidate OV101 (gaboxadol) in patients with an inherited nervous system disorder called Angelman syndrome . More news on: Ovid Therapeutics Inc., Healthcare s...

NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the first patient has been randomized in the company...

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremey Levin, DPhil, MB, BChir, Chairman and Chief Exec...

Gainers:  OpGen (NASDAQ: OPGN ) +79% . Marinus Pharmaceuticals (NASDAQ: MRNS ) +35% . Top Ships (NASDAQ: TOPS ) +25% . Natuzzi S.p.A. (NYSE: NTZ ) +23% . Mereo BioPharma Group (NASDAQ: MREO ) +23% . Ovid Therapeutics (NASDAQ: OVID ) +19% . Owens & Minor (NYSE: OMI ) +19% . ...

OpGen (NASDAQ: OPGN ) +77%  to merge with Curetis N.V. More news on: OpGen, Inc., Top Ships Inc., The Michaels Companies, Inc., Stocks on the move, Read more ...